ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

$10.64  -0.01 (-0.09%)
As of 07/01/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  12/11/2020
Outstanding shares:  284,536,212
Average volume:  4,326,619
Market cap:   $3,030,310,658
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BL53SR3
Valuation   (See tab for details)
PE ratio:   14.78
PB ratio:   2.51
PS ratio:   6.20
Return on equity:   16.96%
Net income %:   41.88%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy